uniQure NV (QURE) Gets a Buy Rating from Cantor Fitzgerald

In a report issued on August 10, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on uniQure NV (NASDAQ: QURE), with a price target of $58. The company’s shares closed on Friday at $35.31.

According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -6.8% and a 44.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $49.17 average price target, which is a 39.3% upside from current levels. In a report issued on August 8, Janney Montgomery also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

Based on uniQure NV’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.59 million. In comparison, last year the company had a GAAP net loss of $21.27 million.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.